Ovarian function, reproduction and strategies for fertility preservation after breast cancer

Critical Reviews in Oncology/Hematology

Volumn 76, Issue 1, 2010, Pages 1-12

  Tomao, Federica ^a,b   Spinelli, Gian Paolo ^b   Panici, Pierluigi Benedetti ^a   Frati, Luigi ^b   Tomao, Silverio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Breast cancer; Fertility; Reproduction

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN; GOSERELIN; METHOTREXATE; PLATINUM DERIVATIVE; TAMOXIFEN; VINCA ALKALOID;

AMENORRHEA; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; CRYOPRESERVATION; DRUG EFFICACY; DRUG SAFETY; FEMALE INFERTILITY; GONADAL DISEASE; HUMAN; INFERTILITY THERAPY; MENOPAUSE; MULTIPLE CYCLE TREATMENT; NIDATION; OVARY FUNCTION; OVARY INSUFFICIENCY; OVULATION INDUCTION; OVULATION INHIBITION; PATIENT COUNSELING; PATIENT SAFETY; PREGNANCY; PREMATURE OVARIAN FAILURE; PREVALENCE; QUALITY OF LIFE; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; INFERTILITY, FEMALE; OVARY; PREGNANCY; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 77956614065     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.12.005     Document Type: Review

References (90)

1. Spitz S. The histological effects of nitrogen mustard on human tumours and tissues. Cancer 1948, 1:383-398.
2. Meistrich M.L., Finch M., da Cunha M.F., Hacker U., Au W.W. Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res 1982, 42:122-131.
3. Clark S.T., Radford J.A., Crowther D., Swindell R., Shalet S.M. Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 1995, 13:134-139.
4. Viviani S., Santoro A., Ragni G., Bonfante V., Bestetti O., Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985, 21:601-605.
5. Kreuser E.D., Xiros N., Hetzel W.D., Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol 1987, 113:260-266.
6. Mackie E.J., Radford M., Shalet S.M. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol 1996, 27:74-78.
7. Wallace W.H., Shalet S.M., Lendon M., Morris-Jones P.H. Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. Int J Androl 1991, 14:312-319.
8. Jerzy E, Tyczynski FB, Maxwell Parkin D, ENCR Cancer facts sheets In: Breast cancer in Europe, vol. 2; December 2002.
9. Hankey B.F., Miller B., Curtis R., et al. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr 1994, 16:7-14.
10. Ghafoor A., Jemal A., Ward E., et al. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003, 53:342-355.
11. Higgins S., Haffty B.G. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer 1994, 73:2175-2180.
12. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14:1718-1729.
13. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:930-942.
14. Shapiro C.L., Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001, 344:1997-2008.
15. Thewes B., Meiser B., Taylor A., et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005, 23:5155-5165.
16. Oktay K., Buyuk E., Libertella N., et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005, 23:4347-4353.
17. Partridge A.H., Gelber S., Peppercorn J., et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004, 22:4174-4183.
18. Degner L.F., Kristjanson L.J., Bowman D., et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997, 277:1485-1492.
19. Chapman R.M. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 1982, 9:84-94.
20. Vujovic S. Aetiology of premature ovarian failure. Menopause Int 2009, 15(June (2)):72-75. Review.
21. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M., Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999, 17:2365-2370.
22. Vegetti W., Marozzi A., Manfredini E., et al. Premature ovarian failure. Mol Cell Endocrinol 2000, 161:53-57.
23. Goldhirsch A., Gelber R.D., Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990, 1:183-188.
24. Levine M.N., Bramwell V.H., Pritchard K.I., et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with nodepositive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998, 16:2651-2658.
25. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000, 169:123-131.
26. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radiochemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma 1999, 33:65-76.
27. Warne G.L., Feirley K.F., Hobbs J.B., Martin F.I. Cyclophosphamide-induced ovarian failure. New Engl J Med 1973, 289:1159-1162.
28. Venturini M., Del Mastro L., Aitini E., et al. Dose-dense adjuvant chemotherapy patients: results from a randomized trial. J Natl Cancer Inst 2005, 97:1724-1733.
29. Hortobagyi G.N., Buzdar A.U., Marcus C.E., Smith T.L. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at MD Anderson Hospital and Tumor Institute. J Natl Cancer Inst Monogr 1986, 1:105-109.
30. Davis L., Klitus M., Mintzer D. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer 2005, 6(5):421-424.
31. Tham Y.L., Sixton K., Weiss H., Elledge R., Friedman L., Kramer R. The rates of chemotherapy-induced amenorrhea in patients treatd with adjuvant doxorubicin and cyclophosphamide followed by taxane. Am J Clin Oncol 2007, 30:126-132.
32. Fornier M.N., Modi S., Panageas K.S., Norton L., Hudis C. Incidence of chemotherapyinduced, long-term amenorrhea in patients with breast carcinoma aged 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005, 104(8):1575-1579.
33. Nabholtz J.M., Pienkowski T., Mackey J., et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer patients: interim analysis of the BCIRG 001 study. Proc Ann Meet Am Soc Clin Oncol 2002, 141. (abstract).
34. Ferretti G., Carlini P., Bria E., et al. Chemotherapy-induced amenorrhea in early breast cancer. Ann Oncol 2006, 17(2):352.
35. Abusief ME, Missmer SA, Ginsburg Weeks JC, Wiener EP, Partridge AH, The effect of paclitaxel, dose density and trastuzumab in chemotherapy-related amenorrhea (CRA) in premenopausal women with breast cancer, San Antonio; 2006, Abstract 2079.
36. Martin M., Pienkowski T., Mackey J., et al. Breast Cancer International Research Group 001 Investigators: adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313.
37. Petrek J.A., Naughton M.J., Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006, 24:1045-1051.
38. Berliere M., Dalenc F., Malingret N., et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 2008, February (8):56.
39. Danforth D.N. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology (Williston) 1991, 5:23-30. discussion 30-21.
40. Kroman N., Jensen M.B., Melbye M., Wohlfahrt J., Mouridsen H.T. Should women be advised against pregnancy after breast-cancer treatment?. Lancet 1997, 350:319-322.
41. Hortobagyi G.N. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004, 100:465-469.
42. Ives A., Saunders C., Bulsara M., Semmens J. Pregnancy after breast cancer: population based study. BMJ 2007, 334:194.
43. Barthelmes L., Davidson L.A., Gaffney C., Gateley C.A. Pregnancy and breast cancer. BMJ 2005, 330:1375-1378.
44. Mintzer D., Glassburn J., Mason B.A., Sataloff D. Breast cancer in the very young patient: a multidisciplinary case presentation. Oncologist 2002, 7:547-554.
45. Blakely L.J., Buzdar A.U., Lozada J.A., et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004, 100:465-469.
46. Sankila R., Heinavaara S., Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect. Am J Obstet Gynecol 1994, 170:818-823.
47. Von Schoultz E., Johansson H., Wilking N., Rutqvist L.E. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995, 13:430-434.
48. Partridge A.H., Ruddy K.J. Fertility and adjuvant treatment in young women with breast cancer. Breast. 2007, 16(December (Suppl. 2)):S175-S181.
49. Sonmezer M., Oktay K. Fertility preservation in young women undergoing breast cancer therapy. The Oncologist 2006, 11:422-434.
50. Horning S.J., Hoppe R.T., Kaplan H.S., Rosenberg S.A. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981, 304:1377-1382.
51. Meistrich M.L., Vassilopoulou-Sellin R., Lipshultz L.I. Gonadal dysfunction. Cancer: principles and practice of oncology, vol. 7 2005, Lippincott Williams and Wilkins, Philadelphia, p. 25602574. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
52. Ataya K., Rao L.V., Lawrence E., et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995, 52:365-372.
53. Ataya K., Pydyn E., Ramahi-Ataya A., et al. Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: preliminary observations. J Clin Endocrinol Metab 1995, 8:790-795.
54. Blumenfeld Z., Avivi I., Linn S., et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996, 11:1620-1626. 20.
55. Blumenfeld Z., Avivi I., Ritter M., et al. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 1999, 6:229-239.
56. Franke H.R., Smit W.M., Vermes I. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy. Gynecol Endocrinol 2005, 20:274-278.
57. Recchia F., Sica G., De Filippis S., et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs 2002, 13:417-424.
58. Urruticoechea A., Arnedos M., Walsh G., Dowsett M., Smith I.E. Ovarian protection with goserelin during adjuvant chemotherapy for premenopausal women with early breast cancer (EBC). Breast Cancer Res Treat Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Breast Cancer Res Treat. 2008, 110(August (3)):411-416.
59. Oktay K., Sonmezer M., Oktem O., Fox K., Emons G., Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007, 12:1055-1066.
60. Lee S.J., Schover L.R., Partridge A.H., et al. American Society of Clinical Oncology: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006, 24:2917-2931.
61. Seli E., Tangir J. Fertility preservation options for female patients with malignancies. Curr Opin Obstet Gynecol 2005, 17:299-308.
62. Maltaris T., Seufert R., Fischl F., et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 2007, 130:148-155.
63. Oktay K., Buyuk E., Davis O., et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003, 18:90-95.
64. Omland A.K., Fedorcsak P., Storeng R., et al. Natural cycle IVF in unexplained, endometriosisassociated and tubal factor infertility. Hum Reprod 2001, 16:2587-2592.
65. Oktay K., Hourvitz A., Sahin G., et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006, 91:3885-3890.
66. Gosden R.G. Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr 2005, 34:60-63.
67. Oktay K., Cil A.P., Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006, 86:70-80.
68. Chian R.C., Buckett W.M., Tulandi T., Tan S.L. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod 2000, 15:165-170.
69. Partridge A., Gelber S., Gelber R.D., Castiglione-Gertsch M., Goldhirsch A., Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007, 43:1646-1653.
70. Baka S.G., Toth T.L., Veeck L.L., Jones H.W., Muasher S.J., Lazendorf S.E. Evaluation of the spindle apparatus of in-vitro matured human oocytes following cryopreservation. Hum Reprod 1995, 10:1816-1820.
71. Oktay K., Tilly J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet 2004, 364:2091-2092.
72. Oktay K., Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 2000, 342:1919.
73. Oktay K., Economos K., Kan M., et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001, 286:1490-1493.
74. Callejo J., Salvador C., Miralles A., et al. Long-term ovarian function evaluation after autografting by implantation with fresh and frozen-thawed human ovarian tissue. J Clin Endocrinol Metab 2001, 86:4489-4494.
75. Donnez J., Dolmans M.M., Demylle D., et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004, 364:1405-1410.
76. Meirow D., Levron J., Eldar-Geva T., et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005, 353:318-321.
77. Liede A., Narod S.A. Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 2002, 20:413-424.
78. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609-1615. 22.
79. Masamura S., Santner S.J., Heitjan D.F., Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995, 80:2918-2925.
80. Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94:606-616.
81. Park M., Davidson R., Fox K. Preservation of fertility and the impact of subsequent pregnancy in patient with premenopausal breast cancer. Semin Oncol 2006, 33:664-671.
82. Steiner A.Z., Terplan M., Paulson R. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod 2005, 20:1511-1515.
83. Klijn J.G., Beex L.V., Mauriac L. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000, 92:903-911.
84. Casper R.F. Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol 2007, 106:71-75.
85. Klopper A., Hall M. New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J 1971, 1:152-154.
86. Boostanfar R., Jain J.K., Mishell D.R., et al. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril 2001, 75:1024-1026.
87. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002, 359:2131-2139.
88. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
89. Mitwally M.F., Casper R.F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001, 75:305-309.
90. Oktay K., Hourvitz A., Sahin G., et al. Letrozole reduces estrogen and gonadotropin undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006, 91:3885-3890.